Education
About Us
Working with TipRanks
Follow Us
BIOTON S.A. (PL:BIO)
:BIO
BIO Stock Chart & Stats
zł4.07
--
Market closed
zł4.07
--
Day’s Range― - ―
52-Week Rangezł3.14 - zł4.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)33.62K
Market Cap
zł349.47M
Enterprise Valuezł422.10M
Total Cash (Recent Filing)zł1.61M
Total Debt (Recent Filing)zł43.33M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding85,864,200
10 Day Avg. Volume22,695
30 Day Avg. Volume33,619
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.42
Price to Sales (P/S)1.19
P/FCF Ratio10.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BIO FAQ
What was BIOTON S.A.’s price range in the past 12 months?
BIOTON S.A. lowest stock price was zł3.14 and its highest was zł4.70 in the past 12 months.
What is BIOTON S.A.’s market cap?
BIOTON S.A.’s market cap is zł349.47M.
When is BIOTON S.A.’s upcoming earnings report date?
BIOTON S.A.’s upcoming earnings report date is Mar 27, 2026 which is in 73 days.
How were BIOTON S.A.’s earnings last quarter?
BIOTON S.A. released its earnings results on Oct 30, 2025. The company reported zł0.049 earnings per share for the quarter, beating the consensus estimate of N/A by zł0.049.
Is BIOTON S.A. overvalued?
According to Wall Street analysts BIOTON S.A.’s price is currently Overvalued.
Does BIOTON S.A. pay dividends?
BIOTON S.A. does not currently pay dividends.
What is BIOTON S.A.’s EPS estimate?
BIOTON S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BIOTON S.A. have?
BIOTON S.A. has 85,864,200 shares outstanding.
What happened to BIOTON S.A.’s price movement after its last earnings report?
BIOTON S.A. reported an EPS of zł0.049 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BIOTON S.A.?
Currently, no hedge funds are holding shares in PL:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BIOTON S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
Technical Analysis
Ryvu Therapeutics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
Selvita SA
―
Mabion SA
―